Zacks: Brokerages Anticipate Ultragenyx Pharmaceutical Inc (RARE) Will Post Quarterly Sales of $18.60 Million
Equities analysts expect Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to announce sales of $18.60 million for the current fiscal quarter, Zacks reports. Seven analysts have provided estimates for Ultragenyx Pharmaceutical’s earnings. The highest sales estimate is $22.10 million and the lowest is $16.10 million. Ultragenyx Pharmaceutical reported sales of $10.68 million during the same quarter last year, which indicates a positive year over year growth rate of 74.2%. The company is scheduled to announce its next quarterly earnings results on Monday, May 6th.
According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full year sales of $99.06 million for the current fiscal year, with estimates ranging from $69.27 million to $127.21 million. For the next financial year, analysts forecast that the business will post sales of $207.34 million, with estimates ranging from $142.30 million to $257.54 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, February 19th. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.74) by $0.01. The business had revenue of $16.26 million during the quarter, compared to the consensus estimate of $13.30 million. Ultragenyx Pharmaceutical had a negative return on equity of 35.26% and a negative net margin of 383.75%.
In other Ultragenyx Pharmaceutical news, CFO Shalini Sharp sold 14,800 shares of the stock in a transaction on Monday, March 18th. The stock was sold at an average price of $70.00, for a total value of $1,036,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 8.40% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. Exane Derivatives purchased a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at $36,000. Meeder Asset Management Inc. increased its position in shares of Ultragenyx Pharmaceutical by 321.1% in the first quarter. Meeder Asset Management Inc. now owns 598 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 456 shares in the last quarter. Bank of Montreal Can increased its position in shares of Ultragenyx Pharmaceutical by 100.9% in the fourth quarter. Bank of Montreal Can now owns 1,079 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 542 shares in the last quarter. Oppenheimer Asset Management Inc. purchased a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at $55,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in shares of Ultragenyx Pharmaceutical by 16.6% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,924 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 274 shares in the last quarter. Institutional investors and hedge funds own 98.62% of the company’s stock.
Shares of NASDAQ RARE opened at $67.79 on Wednesday. Ultragenyx Pharmaceutical has a 1-year low of $37.44 and a 1-year high of $90.98. The firm has a market cap of $3.40 billion, a P/E ratio of -9.17 and a beta of 2.22.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.
Featured Story: Cost of Debt
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.